Research at Abbvie Inc. and Calico Life Sciences LLC has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or PTPN1B. They are reported to be useful for the treatment of cancer, type 2 diabetes and nonalcoholic steatohepatitis (NASH).
Cocrystal Pharma Inc., Merck Sharp & Dohme Corp. and MSD R&D (China) Co. Ltd. have jointly patented new cap-dependent endonuclease (CEN) (influenza virus) inhibitors that are reported to be useful for the treatment of influenza.
Research at Nimbus Saturn Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported in a recent patent to be useful for the treatment of cancer.
Researchers at Flare Therapeutics Inc. have prepared and tested quinoline compounds acting as peroxisome-proliferator receptor γ (PPARγ) inverse agonists reported to be useful for the treatment of bladder cancer.
Indole derivative compounds acting as ferroptosis inhibitors have been reported in a Mitoimmune Therapeutics Inc. patent as potentially useful for the treatment of neurodegeneration, diabetes, stroke, myocardial infarction, liver, lung diseases, eye, renal disorders, among others.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have patented N-acylhydrazone compounds acting as sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers which are described as being potentially useful for the treatment of pain.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly patented aromatic acetylene derivatives acting as UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
Tricyclic fused pyrimidine compounds have been described in a Bristol Myers Squibb Co. patent as HER2 (erB2) and/or HER2 (erB2) mutant inhibitors with potential for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders.
RSS